The study detected FeLV genetic material in the saliva of 4.0% of stray cats tested through a trap–neuter–return program in Switzerland. A positive saliva result alone cannot confirm persistent progressive infection. The study could not detect every form of infection and did not investigate how many cats developed lymphoma or leukemia. These results cannot determine whether the cats had cancer, but they do not show that cancer was absent either.
The study published in Viruses in 2024 (doi: 10.3390/v16030394) used prospective opportunistic sampling of stray cats participating in a trap–neuter–return program in Switzerland. It was an observational study in living cats, not a controlled experiment on infection or oncogenesis; laboratory assay controls do not constitute a clinical control group. Of 1719 samplings, 1711 saliva samples were included and eight samples were excluded. The cats came from 19 of Switzerland's 26 cantons. The observed FeLV sample prevalence was 4.0% (95% CI 3.1–5.0%), assessed through salivary RNA detection as a measure of antigenemia. This figure does not estimate the prevalence of lymphoma, leukemia, or all categories of FeLV infection.
The diagnostic approach does not uniquely identify progressive infection: some early regressive infections can also involve antigenemia or detectable salivary RNA. This is a diagnostic interpretation limitation described by the authors, not a demonstration of infection trajectories through follow-up in this cohort. A positive saliva result alone establishes neither persistent progressive infection nor subsequent malignancy. The absence of blood samples prevented provirus qPCR and detection of provirus-positive, antigen-negative regressive infections; the reported prevalence therefore does not encompass all provirus-carrying cats. Salivary viral loads were semi-quantitative because saliva volume and biological dilution were uncertain.
Sampling depended on the neutering program: five cantons contributed fewer than ten samples each, and seven contributed none. Clinical signs were reported only occasionally, at the discretion of the attending veterinarian and without a standardized protocol. The healthy-versus-sick classification was not a standardized oncology assessment and cannot support a comparison of cats with and without lymphoma or leukemia. The study describes FeLV RNA positivity and geographic clustering, but it did not investigate cancer outcomes or provide a cancer-risk comparison between progressive and regressive infections.
The empirical claims in the source object have evidence level C. The conclusion that infection prevalence cannot establish the incidence of FeLV-associated lymphoma or leukemia is an inference based on the surveillance design, non-standardized clinical reporting, and absence of reported cancer outcomes; it has no assigned evidence level. It does not imply that malignancies were absent. From an oncology perspective, these data provide infection-surveillance context, not evidence about cancer incidence, malignant progression, or mechanisms of oncogenesis.
Salivary FeLV RNA detection showed a sample prevalence of 4.0% (95% CI 3.1–5.0%) among the 1711 stray cats tested through opportunistic sampling. The study provides information on positivity and geographic clustering, with incomplete geographic coverage. A positive saliva result does not uniquely distinguish progressive infection from some early regressive infections.
These data do not establish the prevalence of all categories of FeLV infection, because provirus-positive, antigen-negative regressive infections could not be detected. They also do not establish which saliva-positive cats had persistent progressive infection, their cancer status, the incidence of lymphoma or leukemia, malignant progression, mechanisms of oncogenesis, or differences in cancer risk between infection categories. The lack of investigated cancer outcomes does not demonstrate an absence of cancer.
Excerpt verified in the source — verbatim, in the source's own language“Overall, the FeLV prevalence in the 1711 stray cats was 4.0% (95% CI 3.1–5.0%).”
Prevalence was assessed by salivary RNA detection as a measure for antigenemia. This is not a prevalence estimate for lymphoma, leukemia, or all FeLV infection categories.
Excerpt verified in the source — verbatim, in the source's own language“Both methods primarily identify cats with a progressive infection, but they also identify a part of the regressively infected cats in the very early phase of the infection when these cats can also be antigenemic/salivary viral RNA positive.”
The authors describe a diagnostic interpretation limitation, not infection trajectories demonstrated by follow-up in this cohort. A positive saliva result alone does not establish persistent progressive infection or subsequent malignancy.
Excerpt verified in the source — verbatim, in the source's own language“Due to the unavailability of blood samples, we could not test for FeLV provirus with qPCR. Consequently, stray cats with a regressive FeLV infection, provirus PCR positive but antigen negative [ 7 , 8 ], were not detected in the current study.”
The reported prevalence does not encompass all provirus-carrying cats. The study provides no cancer-risk comparison between progressive and regressive infection categories.
Excerpt verified in the source — verbatim, in the source's own language“However, it was not the goal of the present study to investigate clinical signs in the sampled cats, and thus, the study setup was not designed for this. Clinical signs were only occasionally reported and not according to an exact protocol; thus, the reported data largely depended on the attending veterinarian.”
The healthy-versus-sick classification is not a standardized oncology assessment and cannot be interpreted as a comparison of cats with and without lymphoma or leukemia.
Excerpt verified in the source — verbatim, in the source's own language“This prospective study employed opportunistic sampling. We included saliva samples collected from cats subjected to a trap–neuter–return program (NetAP, Esslingen, Switzerland).”
This establishes an observational sampling design, not a controlled experiment on infection or oncogenesis. Laboratory assay controls do not constitute a clinical control group.
This is an inference from the infection-surveillance design, non-standardized clinical reporting, and absence of reported cancer outcomes. It does not imply that malignancies were absent.
AVA